Another study by Wang et al. has also found that GLP-1 analogues, specifically semaglutide, are linked to a significantly lower risk of suicidal behaviors compared to non-GLP-1 analogues for either treatment of obesity (e.g. naltrexone, bupropion, etc.)or diabetes (e.g. metformin, insulin etc.)[10]. This evidence concerns the gene GLP1R and diabetes mellitus.